A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder

NCT01114698 Phase 2 TERMINATED

The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 2
Status	TERMINATED
Enrolment	12
Start date	2011-03
Completion	2012-02

Conditions

• Depression

Interventions

• Venlafaxine XR
• Placebo
• JNJ26489112

Primary outcomes

• Change from baseline in Montgomery-Asberg Depression Rating Scale (10 item diagnostic questionnaire measuring the severity of depression) — Baseline and 6 weeks

Countries

United States